Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 1: of Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Josef Smolen (898)
Ronald van Vollenhoven (4148)
Arthur Kavanaugh (2683)
Vibeke Strand (410780)
Jiri Vencovsky (473759)
Michael Schiff (274089)
Robert LandewĂŠ (3445133)
Boulos Haraoui (63749)
Catherine Arendt (3584990)
Irina Mountian (3351668)
David Carter (117501)
DĂŠsirĂŠe van der Heijde (3445130)

September 2015

Supplementary material. Additional supplementary data tables and figures referred to in the manuscri...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Mean change from baseline in HAQ-DI by visit (ITT population). Abbreviations: Adalimumab-EU adalimum...

Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two tre...

Additional file 9: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

ADA and NAb incidence by study visit (safety population). Abbreviations: ADA anti-drug antibody, NAb...

Additional file 8: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

All-causality treatment-emergent adverse events in at least 2% of patients in any treatment arm (saf...

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

Additional file 2: of Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

Joost Swart (6158915)
Gabriella Giancane (5081474)
Gerd Horneff (3415988)
Bo Magnusson (6158918)
Michael Hofer (5118887)
Đkaterina Alexeeva (6158972)
Violeta Panaviene (6158930)
Brigitte Bader-Meunier (363218)
Jordi Anton (6158936)
Susan Nielsen (5173895)
Fabrizio De Benedetti (637645)
Sylvia Kamphuis (4751061)
Valda StaĹÄviÄa (6158975)
Maria Tracahana (6158948)
Laura Ailioaie (6158951)
Elena Tsitsami (6158957)
Ariane Klein (3415976)
Kirsten Minden (3415979)
Ivan Foeldvari (4578778)
Johannes Haas (4612090)
Jens Klotsche (93841)
Anna Horne (6158963)
Alessandro Consolaro (5081480)
Francesca Bovis (403189)
Francesca Bagnasco (6158969)
Angela Pistorio (326468)
Alberto Martini (8758)
Nico Wulffraat (28328)
Nicolino Ruperto (3689917)

December 2018

Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...

Additional file 2: of Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials

Xavier Teitsma (3514304)
Anne Marijnissen (3514307)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)
Johannes Jacobs (3514301)

September 2016

Forest plots of American College of Rheumatology 20 (a), 50 (b), and 70 (c) responses. Meta-analyses...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 1: of Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Josef Smolen (898)
Ronald van Vollenhoven (4148)
Arthur Kavanaugh (2683)
Vibeke Strand (410780)
Jiri Vencovsky (473759)
Michael Schiff (274089)
Robert LandewĂŠ (3445133)
Boulos Haraoui (63749)
Catherine Arendt (3584990)
Irina Mountian (3351668)
David Carter (117501)
DĂŠsirĂŠe van der Heijde (3445130)

September 2015

Supplementary material. Additional supplementary data tables and figures referred to in the manuscri...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Mean change from baseline in HAQ-DI by visit (ITT population). Abbreviations: Adalimumab-EU adalimum...

Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two tre...

Additional file 9: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

ADA and NAb incidence by study visit (safety population). Abbreviations: ADA anti-drug antibody, NAb...

Additional file 8: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

All-causality treatment-emergent adverse events in at least 2% of patients in any treatment arm (saf...

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

Additional file 2: of Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

Joost Swart (6158915)
Gabriella Giancane (5081474)
Gerd Horneff (3415988)
Bo Magnusson (6158918)
Michael Hofer (5118887)
Đkaterina Alexeeva (6158972)
Violeta Panaviene (6158930)
Brigitte Bader-Meunier (363218)
Jordi Anton (6158936)
Susan Nielsen (5173895)
Fabrizio De Benedetti (637645)
Sylvia Kamphuis (4751061)
Valda StaĹÄviÄa (6158975)
Maria Tracahana (6158948)
Laura Ailioaie (6158951)
Elena Tsitsami (6158957)
Ariane Klein (3415976)
Kirsten Minden (3415979)
Ivan Foeldvari (4578778)
Johannes Haas (4612090)
Jens Klotsche (93841)
Anna Horne (6158963)
Alessandro Consolaro (5081480)
Francesca Bovis (403189)
Francesca Bagnasco (6158969)
Angela Pistorio (326468)
Alberto Martini (8758)
Nico Wulffraat (28328)
Nicolino Ruperto (3689917)

December 2018

Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...

Additional file 2: of Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials

Xavier Teitsma (3514304)
Anne Marijnissen (3514307)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)
Johannes Jacobs (3514301)

September 2016

Forest plots of American College of Rheumatology 20 (a), 50 (b), and 70 (c) responses. Meta-analyses...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 1: of Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Josef Smolen (898)
Ronald van Vollenhoven (4148)
Arthur Kavanaugh (2683)
Vibeke Strand (410780)
Jiri Vencovsky (473759)
Michael Schiff (274089)
Robert LandewĂŠ (3445133)
Boulos Haraoui (63749)
Catherine Arendt (3584990)
Irina Mountian (3351668)
David Carter (117501)
DĂŠsirĂŠe van der Heijde (3445130)

September 2015

Supplementary material. Additional supplementary data tables and figures referred to in the manuscri...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Abstract

Extracted data

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Abstract

Extracted data

Related items

Related items